Eli Lilly and Company Stock News

MeiraGTx Holdings has signed a deal with Eli Lilly , potentially worth over $475 million, granting the pharma giant rights to its experimental gene therapy for a rare, inherited disorder that causes severe vision loss from birth.

The futures are trading higher as the new week begins, with most investors and traders relieved that last week has come to a close.

Eli Lilly has been investing in radiopharmaceuticals, which can help revolutionize cancer care in the future. Its early Alzheimer's drug, Kisunla, has blockbuster potential, and if efforts at early detection are successful, it could have even more upside.

Eli Lilly (LLY 1.39%) and Novo Nordisk (NVO 1.89%) agreed to lower prices for their weight loss treatments in exchange for lower tariffs and expanded access.

The watchlist stocks have bucked the market's recent volatility.

Eli Lilly delivered fantastic third-quarter results, largely thanks to tirzepatide. The company's current lineup and pipeline make the stock attractive.

LLY's Mounjaro and Zepbound deliver accelerated weight loss rates compared to NVO's Wegovy, which perhaps explains the former's triple digits GLP-1 revenue growth on a YoY basis. This is on top of LLY's expanding US incretin analogs market share on a QoQ/ YoY basis, aided by the increased manufacturing capacity despite the CVS headwinds. Given the prior sideways trading cadence since early 2024...

Eli Lilly has plenty of medium-term catalysts that should power a strong performance through 2030. Berkshire Hathaway, by contrast, is facing some headwinds that may limit its upside.